Dr. Wolfgang Dummer M.D., Ph.D. Net Worth

The estimated Net Worth of Wolfgang Dummer is at least $1.56 Million dollars as of 2 February 2023. Dr Dummer owns over 5,389 units of Rigel Pharmaceuticals stock worth over $939,793 and over the last 6 years he sold RIGL stock worth over $8,946. In addition, he makes $614,363 as Exec. VP & Chief Medical Officer at Rigel Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dr D RIGL stock SEC Form 4 insiders trading

Dr has made over 1 trades of the Rigel Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 5,389 units of RIGL stock worth $8,946 on 2 February 2023.

The largest trade he's ever made was selling 5,389 units of Rigel Pharmaceuticals stock on 2 February 2023 worth over $8,946. On average, Dr trades about 599 units every 0 days since 2018. As of 2 February 2023 he still owns at least 72,459 units of Rigel Pharmaceuticals stock.

You can see the complete history of Dr Dummer stock trades at the bottom of the page.

Dr. Wolfgang Dummer M.D., Ph.D. biography

Dr. Wolfgang Dummer M.D., Ph.D. is the Exec. VP & Chief Medical Officer at Rigel Pharmaceuticals.

What is the salary of Dr D?

As the Exec. VP & Chief Medical Officer of Rigel Pharmaceuticals, the total compensation of Dr D at Rigel Pharmaceuticals is $614,363. There are 3 executives at Rigel Pharmaceuticals getting paid more, with David A. Santos having the highest compensation of $1,034,977.

How old is Dr D?

Dr D is 55, he's been the Exec. VP & Chief Medical Officer of Rigel Pharmaceuticals since . There are 5 older and 1 younger executives at Rigel Pharmaceuticals. The oldest executive at Rigel Pharmaceuticals is Raul R. Rodriguez, 60, who is the Pres, CEO & Director.

What's Dr D's mailing address?

Wolfgang's mailing address filed with the SEC is C/O ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE, WA, 98102.

Insiders trading at Rigel Pharmaceuticals

Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke, and Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.

What does Rigel Pharmaceuticals do?

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

Complete history of Dr Dummer stock trades at Rigel Pharmaceuticals, Alpine Immune Sciences Inc, and Aridis Pharmaceuticals Inc

Rigel Pharmaceuticals executives and stock owners

Rigel Pharmaceuticals executives and other stock owners filed with the SEC include:

• David A. Santos,
  Exec. VP & Chief Commercial Officer
• Raul R. Rodriguez,
  Pres, CEO & Director
• Dolly A. Vance,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Dr. Wolfgang Dummer M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Dean L. Schorno CPA,
  Exec. VP & CFO
• Julie Patel,
  Sr. VP of HR
• Tarek Sallam,
  VP of Marketing
• Dr. Esteban S. Masuda,
  Exec. VP of Research
• Joseph Lasaga,
  Sr. VP of Corp. Devel.
• Gary A Lyons,
  
• Brian L. Kotzin,
  
• Jane Wasman,
  
• Kamil Ali Jackson,
  
• Donald G Payan,
  Executive V.P. and CSO
• Peter S Ringrose,
  Director
• Keith Katkin,
  Director
• Ryan D Maynard,
  VP Finance, Acting CFO
• Esteban Masuda,
  Sr. VP Research
• Walter H Moos,
  
• Bradford S Goodwin,
  Director
• Stephen A Sherwin,
  Director
• Eldon C. Iii Mayer,
  EVP & Chief Commercial Officer
• James H Welch,
  VP, CFO and Corp Secretary
• Alan D Frazier,
  Director
• Elliot B Grossbard,
  Sr VP of Med Development
• Anthony Gregg Lapointe,
  
• Nelson Cabatuan,
  VP,Finance & Princ.Acctg. Off.
• Stacy Markel,
  EVP Human Resources
• Joseph Lasaga,
  Sr.VP Bus.Dev.Alliance Mgmt.
• Anne Marie Duliege,
  EVP & Chief Medical Officer
• Partners Ii Incalta Biophar...,
  
• Nicholas J Iii Simon,
  Director
• Bioventures Iii Qp Lpmpm Bi...,
  
• Lukegadicke Ansbert Evnin,
  
• Dennis Henner,
  Director
• Jeanalta Partnersalta Calif...,
  
• Nicholas Galakatos,
  10% owner
• Michael Steinmetz,
  10% owner
• Partners Ii Incalta Biophar...,
  
• Ansbert Gadicke,
  10% owner
• Luke Evnin,
  10% owner
• Bioequities Master Fund Lpm...,
  
• Healthcare Iv Lpfhm Iv Lpfh...,
  
• Lisa Rojkjaer,
  EVP, Chief Medical Officer
• James M Gower,
  CEO and Chairman of the Board
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Hollings Renton,
  Director
• James Edeerfield Capital Lp...,
  
• James Edeerfield Capital Lp...,
  
• Jean Deleage,
  Director
• Robin D G Cooper,
  Sr. V.P. Pharmaceutical Scs.
• David A Santos,
  EVP, Chief Commercial Officer
• Wolfgang Dummer,
  EVP & CMO
• Alison L. Hannah,
  
• Dean L Schorno,
  EVP & Chief Financial Officer
• Dolly Vance,
  EVP Corp. Affairs, G.C., Sect.
• Raymond J. Furey,
  EVP, GC, CCO & Corp Sec